Biocon’s Pertuzumab Faces USITC Review
The U.S. International Trade Commission (USITC) has received a complaint alleging that certain biosimilar versions of the cancer drug pertuzumab ...
The U.S. International Trade Commission (USITC) has received a complaint alleging that certain biosimilar versions of the cancer drug pertuzumab ...